Elevated Serum Interleukin-15 Level in Acute Graft-Versus-Host Disease after Hematopoietic Cell Transplantation

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 12, 2003, Pages 960-964

  Chik, Ki Wai ^a,b   Li, Karen ^a   Pong, Henry ^a   Shing, Matthew Ming Kong ^a   Li, Chi Kong ^a   Yuen, Patrick Man Pan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acute graft versus host disease; Cytokines; Interleukin 15

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MALE; PRIORITY JOURNAL; STEM CELL;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-15; MALE; PREDICTIVE VALUE OF TESTS; TH1 CELLS; TH2 CELLS;

EID: 0347384007     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200312000-00011     Document Type: Article

References (23)

1. Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 1992;10:1-14.
2. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med. 1991; 324:667-674.
3. Ferrara JL. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant. 1998;21(S3):S13-S15.
4. Imamura M, Hashino S, Kobayashi S, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-γ, and tumor necrosis factor-α, in graft-versus-host disease. Bone Marrow Transplant. 1994;13:745-751.
5. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553-558.
6. McDyer JF, Wu CY, Seder RA. The regulation of IL-12: its role in infectious, autoimmune, and allergic diseases. J Allergy Clin Immunol. 1998; 102:11-15.
7. Kennedy MK, Park LS. Characterization of interleukin-15 and the IL-15 receptor complex. J Clin Immunol. 1996;16:134-143.
8. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marow from HLA matched sibling donors. Transplantation. 1974;18:295-304.
10. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330: 827-838.
11. Hedeker D, Gibbons RD. MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed. 1996;49:229-252.
12. Hill GR, Cooke KR, Brinson YS, et al. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1999;67:1478-1480.
13. Carayol G, Bourhis J, Guillard M, et al. Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease. Transplantation. 1997;63:1307-1313.
14. Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning-an alternative target for modulation of acute GVHD and complications following allogeneic bone marrow transplantation? Leukemia Lymphoma. 1997;25:214-217.
15. Baker KS, Allen RD, Roths JB, et al. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplant. 1995;15:595-603.
16. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66: 863-871.
17. Abu-Ghosh A, Goldman S, Slone V, et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 1999;24:535-544.
18. Yabe M, Yabe H, Hattori K, et al. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients. Bone Marrow Transplant. 1999;24:29-34.
19. Kumaki S, Minegishi M, Fujie H, et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Intl J Hematol. 1998;67: 307-312.
20. Vogelsang GB. Advances in the treatment of graft-versus-host disease. Leukemia. 2000;14:509-510.
21. Przepiorka D, Keman NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83-89.
22. Koh MBC, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23:1071-1079.
23. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95:1572-1579.